Sigyn Therapeutics, Inc. (SIGY) — SEC Filings
Sigyn Therapeutics, Inc. (SIGY) — 23 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 12 8-K, 6 10-Q, 2 10-K.
View Sigyn Therapeutics, Inc. on SEC EDGAR
Overview
Sigyn Therapeutics, Inc. (SIGY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Sigyn Therapeutics, Inc. (SIGY) reported no revenue for the nine months ended September 30, 2025, consistent with the prior year. The company's net loss decreased to $2,698,254 for the nine months ended September 30, 2025, from $2,817,394 in the same period of 2024. For the three months ended Septem
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 20 neutral. The dominant filing sentiment for Sigyn Therapeutics, Inc. is neutral.
Filing Type Overview
Sigyn Therapeutics, Inc. (SIGY) has filed 6 10-Q, 12 8-K, 2 10-K, 1 8-K/A, 1 S-1/A, 1 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of SIGY's 19 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(2,698,254) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $85,571 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Industry Context
The biotechnology and medical device industry is highly competitive and capital-intensive, with significant R&D investment required for product development and regulatory approval. Companies often pivot to larger or more promising markets, as Sigyn is attempting with its move into cardiovascular disease, a sector with established players and significant market potential but also high barriers to entry.
Top Tags
10-Q (4) · material-agreement (3) · corporate-action (3) · Sigyn Therapeutics (3) · administrative-change (3) · Biotechnology (2) · Medical Devices (2) · Clinical Trials (2) · equity-sale (2) · company-information (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net revenues | $0 | for the nine months ended September 30, 2025, indicating no commercial sales |
| Net loss | $(2,698,254) | for the nine months ended September 30, 2025, a decrease from $(2,817,394) in 2024 |
| Cash | $85,571 | as of September 30, 2025, up from $12,144 at December 31, 2024 |
| Accumulated deficit | $(17,379,978) | as of September 30, 2025, highlighting significant historical losses |
| Working capital deficit | $(3,903,920) | as of September 30, 2025, indicating short-term liquidity challenges |
| Net cash provided by financing activities | $719,635 | for the nine months ended September 30, 2025, crucial for funding operations |
| Research and development expenses | $46,004 | for the nine months ended September 30, 2025, a significant reduction from $679,183 in 2024 |
| Shares of common stock outstanding | 1,605,377 | as of November 14, 2025 |
| Net Loss | $2,119,751 | For the six months ended June 30, 2025, an increase from $1,620,471 in 2024. |
| Net Revenues | $0 | For the three and six months ended June 30, 2025 and 2024. |
| Research and Development Expenses | $16,323 | For the six months ended June 30, 2025, a significant decrease from $473,022 in 2024. |
| Inducement of Preferred Shares | $845,901 | A major component of other expense for the six months ended June 30, 2025. |
| Total Other Expense | $1,104,179 | For the six months ended June 30, 2025, up from $387,697 in 2024. |
| Shares of Common Stock Outstanding | 1,605,377 | As of September 5, 2025. |
| Net Loss Per Share | $1.32 | For the six months ended June 30, 2025, compared to $1.31 in 2024. |
Forward-Looking Statements
- {"claim":"Brio Capital Master Fund Ltd. has either increased or decreased its stake in Sigyn Therapeutics, Inc.","entity":"Brio Capital Master Fund Ltd.","targetDate":"N/A","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Sigyn Therapeutics, Inc. (SIGY)?
Sigyn Therapeutics, Inc. has 23 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SIGY filings?
Across 23 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 20 neutral. The dominant sentiment is neutral.
Where can I find Sigyn Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sigyn Therapeutics, Inc. (SIGY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sigyn Therapeutics, Inc.?
Key financial highlights from Sigyn Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SIGY?
The investment thesis for SIGY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sigyn Therapeutics, Inc.?
Executive information for Sigyn Therapeutics, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Sigyn Therapeutics, Inc. stock?
Of SIGY's 19 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Sigyn Therapeutics, Inc.?
Recent forward-looking statements from Sigyn Therapeutics, Inc. include guidance on {"claim":"Brio Capital Master Fund Ltd. has either increased or decreased its stake in Sigyn Therapeutics, Inc.","entity.